Thomson Reuters (TSE:TRI – Get Free Report) (NYSE:TRI) was upgraded by The Goldman Sachs Group from a “hold” rating to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.
Several other analysts have also recently commented on the stock. Scotiabank upgraded shares of Thomson Reuters from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, August 6th. BMO Capital Markets increased their target price on shares of Thomson Reuters from C$280.00 to C$308.00 in a report on Wednesday, July 16th. Wells Fargo & Company raised Thomson Reuters from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 9th. TD Securities raised Thomson Reuters from a “hold” rating to a “buy” rating and raised their price objective for the company from C$275.00 to C$285.00 in a research note on Thursday, August 28th. Finally, National Bankshares boosted their target price on Thomson Reuters from C$286.00 to C$300.00 and gave the stock an “outperform” rating in a research report on Thursday, July 10th. Four investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Thomson Reuters currently has a consensus rating of “Buy” and a consensus price target of C$265.80.
View Our Latest Research Report on TRI
Thomson Reuters Price Performance
Thomson Reuters Company Profile
Thomson Reuters is the result of the $17.6 billion megamerger of Canada’s Thomson and the United Kingdom’s Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE.
Featured Articles
- Five stocks we like better than Thomson Reuters
- Bank Stocks – Best Bank Stocks to Invest In
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- How to Short a Stock in 5 Easy Steps
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Thomson Reuters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thomson Reuters and related companies with MarketBeat.com's FREE daily email newsletter.